glasdegib   Click here for help

GtoPdb Ligand ID: 8201

Synonyms: Daurismo® | PF 04449913 | PF-04449913
Approved drug
glasdegib is an approved drug (FDA (2018), EMA (2020))
Compound class: Synthetic organic
Comment: Glasdegib is a potent and orally active inhibitor of the hedgehog signalling pathway, that acts as an antagonist of the class frizzled GPCR, smoothened (SMO) [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 96.84
Molecular weight 374.19
XLogP 2.15
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES N#Cc1ccc(cc1)NC(=O)NC1CCN(C(C1)c1nc2c([nH]1)cccc2)C
Isomeric SMILES N#Cc1ccc(cc1)NC(=O)N[C@@H]1CCN([C@H](C1)c1nc2c([nH]1)cccc2)C
InChI InChI=1S/C21H22N6O/c1-27-11-10-16(24-21(28)23-15-8-6-14(13-22)7-9-15)12-19(27)20-25-17-4-2-3-5-18(17)26-20/h2-9,16,19H,10-12H2,1H3,(H,25,26)(H2,23,24,28)/t16-,19-/m1/s1
InChI Key SFNSLLSYNZWZQG-VQIMIIECSA-N
No information available.
Summary of Clinical Use Click here for help
Glasdegib (as research code PF-04449913) was evaluated in clinical trials for various hematologic malignancies. Phase 2 results from trial NCT01546038 were published by Cortes et al. in 2018, which indicated that glasdegib plus cytarabine/daunorubicin was well tolerated and achieved 40% complete remission in patients ≥55 years old with newly-diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes [1]. Click here to link to ClinicalTrials.gov's full listing of PF-04449913 trials.

Following 'Priority Review', the FDA approved glasdegib (in November 2018) as a first-line therapy (in combination with low dose cytarabine chemotherapy) for AML in patients ≥75 years who are too fragile (due to chronic ill health or other comorbidities) to tolerate more intensive and toxic chemotherapy.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01546038 A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 2 Interventional Pfizer